Pulmuone Corporate

As of June 30, 2026, Pulmuone Corporate carries a market capitalization of 336.47B, placing it among publicly traded companies globally. Its enterprise value stands at 1.69T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Pulmuone Corporate's next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, Pulmuone Corporate has 36.89M shares outstanding.

As of June 30, 2026, Pulmuone Corporate trades at a trailing price-to-earnings ratio of 7.69. The price-to-sales ratio is 0.10, and the price-to-book ratio stands at 1.00.

As of June 30, 2026, Pulmuone Corporate trades at an EV/EBITDA multiple of 6.07 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.48 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 15.96 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Pulmuone Corporate trades at an EV/FCF ratio of 17.42, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.69T versus a market cap of 336.47B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Pulmuone Corporate maintains a current ratio of 0.68, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 195.98, indicating elevated leverage, while an interest coverage ratio of 4.53 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Pulmuone Corporate posted a return on equity (ROE) of 14.61, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.41 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.90, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.03, useful for judging operating efficiency across full business cycles. The company generates approximately 6.45B in revenue per employee across its workforce of 541.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 13.49 indicates how many times Pulmuone Corporate sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Pulmuone Corporate recorded 13.69B in income tax expense. That works out to an effective tax rate of 24.32, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 56.28B, leaving 43.76B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Pulmuone Corporate's stock has declined approximately 39.93% over the past 52 weeks. The 50-day moving average sits at 9,079.60, while the 200-day moving average is 10,769.35.

Over the twelve months ended June 30, 2026, Pulmuone Corporate generated 3.49T in revenue and converted that into 43.76B in net income, yielding earnings per share of 975.22. EBITDA reached 278.44B, while operating income came in at 106.01B.

As of June 30, 2026, Pulmuone Corporate holds 164.54B in cash and equivalents against 1.23T in total debt, resulting in a net debt position of 681.10B. Total book value stands at 335.74B, with working capital of -372.24B providing operational flexibility.

Pulmuone Corporate produced 189.23B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -138.68B in capital expenditures, free cash flow totaled 50.55B - equivalent to 1,370.15 per share.

Over the twelve months ended June 30, 2026, Pulmuone Corporate posted a gross margin of 24.79, reflecting its pricing power and cost economics. The operating margin of 3.04 and net profit margin of 1.25 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Pulmuone Corporate paid dividends of 640.75 per share. The dividend payout ratio of 57.07 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 12.69, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 27.91, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Pulmuone Corporate shareholders.

Pulmuone Corporate's most recent stock split took place on May 7, 2019 with a 1:10 split ratio.

As of June 30, 2026, Pulmuone Corporate has an Altman Z-Score of 1.74, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.